Arbutus Launches $230M Dutch Auction Tender Offer at $5.00–$5.75
ABUS sits 53% above its 52-week low of $3.44.
Summary
Arbutus Biopharma announced a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at $5.00–$5.75 per share, expected to commence August 24, 2026.
Key Events · Financing and Capital Events · ABUS
-
Dutch Auction Tender Offer Announced
Arbutus plans to repurchase up to US$230 million of common shares through a modified Dutch auction tender offer at a price range of US$5.00 to US$5.75 per share.
-
Offer Timeline
The offer is expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, subject to regulatory exemptive relief.
-
Funding Source
The repurchase will be funded entirely from cash on hand, which was bolstered by the $178.4 million Moderna settlement payment received in July 2026.
-
Premium to Market
The offer price range of $5.00–$5.75 is at or above the current stock price of $5.27, indicating a willingness to pay a premium to return capital.
Analysis · ABUS · Life Sciences
Arbutus is moving forward with its previously announced $230 million share repurchase via a modified Dutch auction tender offer. The price range of $5.00 to $5.75 brackets the current stock price of $5.27, indicating the company is willing to pay a premium to return capital to shareholders. This is a significant return of capital, representing roughly 24% of the company's market cap, and signals management's confidence in the company's cash position following the Moderna settlement.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1987 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.7M. The 52-week trading range was $3.44 to $5.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.